Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .
Clinical efficacy of ferric carboxymaltose treatment in patients with restless legs syndrome.
OBJECTIVE There have been three r and omized , placebo-controlled , double-blind studies of intravenous iron in restless legs syndrome ( RLS ) , with differing outcomes . The one positive study used ferric carboxymaltose ( FCM ) at a total dose of 1000 mg . The purpose of this study was to replicate and extend the findings from the prior FCM study . METHODS Non-anemic , idiopathic RLS patients were enrolled in a r and omized , double-blinded , placebo-controlled study and received either 1000 mg FCM or placebo as a single infusion ( phase I ) . Subjects were off any RLS medications for at least two weeks prior to baseline assessment . The primary outcome variable was change from baseline at week 6 on the International Restless Legs Syndrome Severity ( IRLSS ) scale and a subject-completed , visual analog scale ( VAS ) of severity . Phase II of the study involved long-term ( 30 weeks ) follow-up after completion of the six-week efficacy phase . RESULTS At week 6 postinfusion , FCM compared to placebo recipients showed significantly greater change from baseline for both primary outcome measures ( IRLSS scale , -11.9 ± 8.04 vs -7.88 ± 5.89 , p = 0.03 ; VAS , -40.6 ± 22.7 vs -21.3 ± 20.0 , p = 0.001 ) . None of the secondary outcome variables showed a significant difference at week 6 . After six weeks of treatment , the FCM group had 19 ( 59.4 % ) responders , of which 12 had IRLSS scores < 10 ( " remitters " ) . Twelve ( 37.5 % ) of the 32 subjects treated with iron in phase I remained free of further RLS medications at 30 weeks . There were no serious adverse events observed in this study . CONCLUSION Two studies now support the value of FCM treatment both in the short term ( six weeks ) and long term ( 30 weeks ) for improving RLS symptoms
Quality -of-life scores ( Piper Fatigue Scale MD 0.73 , 95 % CI 0.29 to 1.18 ; I2 = 0 % ; studies = 3 ) and peak oxygen consumption ( MD 2.77 mL/kg/min , 95 % CI -0.89 to 6.43 ; I2 = 36 % ; 2 studies , 32 participants ) were associated with very low- quality evidence , and we remain uncertain about the role of intravenous iron for these metrics .
Current evidence is insufficient to show benefit of intravenous iron preparations for the treatment of non-anaemic iron deficiency across a variety of patient population s , beyond stating that it may result in a small , clinical ly insignificant increase in haemoglobin concentration .
BACKGROUND Iron deficiency is one of the most common nutritional deficiencies , and has a number of physiological manifestations .
Early , or non-anaemic iron deficiency can result in fatigue and diminished exercise capacity .
Oral iron preparations have a high incidence of intolerable side effects , and are ineffective in certain forms of iron deficiency .
Consequently , intravenous iron preparations are increasingly used in the treatment of non-anaemic iron deficiency .
The newer , more stable iron preparations in particular purport to have a lower incidence of side effects , and are now used across a range of different patient population s. OBJECTIVES To assess the effects of intravenous iron therapy in the treatment of adults with non-anaemic iron deficiency .